

# Supporting Chronic Disease Management, Shaping a Healthy China

Source: <https://www.bayer.com.cn/index.php/NewsCenter/newsDetail/id/370?l=en-us>



---

The extended Beijing site has become the largest pharmaceuticals packaging site for Bayer Pharmaceuticals Division's global production network.

---

**Beijing, November 18, 2016**— Bayer inaugurated the extension program of its Pharmaceuticals Product Supply Beijing Site today. As the largest pharmaceuticals packaging site for Bayer Pharmaceuticals Division's global production network, the extended Beijing site will ensure Bayer's reliable supply of high-quality prescription drugs for more Chinese patients and physicians, thereby helping to address the pressing challenges of chronic disease management in China. Officials from Beijing Municipal Government, Beijing Economic-Technological Development Area, German Embassy in China, European Union Chamber of Commerce, German

Chamber of Commerce, and relevant ministries, chronic disease experts from home and abroad, member of the Board of Management of Bayer AG, and other senior managers of Bayer global & China were among the attendees of the inauguration ceremony.



### *Bayer Pharmaceuticals Product Supply Beijing Site Extension Program inaugurated*

“As a trusted partner to China, Bayer is on a constant mission to further integrate China into our global value chain via more sustainable and high-value investment blueprints. Arriving two years after the signing of a significant investment agreement of approximately EUR 100 million, the inauguration of the extension program marks a new milestone in the history of Bayer Pharmaceuticals Division. The move strongly promotes the strategic position of China in Bayer’s international supply system for prescription drugs, and again demonstrates the unswerving confidence and commitment to our largest single market in Asia,” said Johannes Dietsch, Member of the Board of Management of Bayer AG and Chief Financial Officer of Bayer AG.



*Johannes Dietsch, Member of the Board of Management of Bayer AG and Chief Financial Officer of Bayer AG, delivered a speech*

A mixture of factors represented by the aging population and shift in people's lifestyle leads to the prevalence of chronic diseases that casts increasing burden on the whole society, which is characterized by "large number of patients, considerable medical cost, long duration of illness, heavy demand of service". According to the statistics, over 260 million people in China are diagnosed as chronic disease patients[1]; 25.2% of Chinese citizens aged 18 and above are suffering from hypertension, and 9.7% from diabetes[2]. Meanwhile, deaths from chronic diseases have accounted for a staggering 85%[3] of all deaths in China, imposing tremendous burden for patient families and China's economy.

In 2013, the World Health Organization released the Global Target 25 by 2025, calling on countries around the world to reduce premature deaths from non-communicable diseases by 25% by 2025[4]. China's national agenda of Healthy China 2030 recently lists chronic disease management as one of the country's strategic tasks in the next 15 years. To deliver the goals set by the Global Target 25 by 2025 and the Healthy China 2030

Agenda, it is imperative for China to ensure that more patients and physicians could have access to safer chronic disease solutions with better efficacy, in addition to enhancing public literacy on chronic disease management and reinforcing treatment capabilities of local physicians.

After the completion of the extension program, Bayer Pharmaceuticals Product Supply Beijing Site doubles its production capacity, which ensures the reliable supply of Bayer's high-quality products such as Glucobay<sup>®</sup>, Adalat<sup>®</sup>, Bayaspirin<sup>®</sup>, to better meet the evolving demands of patients with cardiovascular diseases, diabetes, etc. The extension program integrates world-class manufacturing facilities including full automation logistic areas, most modern analytical laboratories, and high-speed packaging lines. Furthermore, Bayer introduced a world-leading lean operational concept and advanced quality control systems to effectively raise production efficiency, and guarantee that all products available to patients have met the quality standards universally implemented by Bayer Pharmaceuticals worldwide.



*The extended Beijing site has become the largest pharmaceuticals packaging site for Bayer Pharmaceuticals Division's global production network*

“As a promoter of chronic disease management in China and a trustworthy partner, Bayer has always been dedicated to leveraging its expertise in disease treatment and extensive resources to help China build a well-rounded framework to deal with chronic diseases. We pursue and ensure medication accessibility, in addition to actively promoting public awareness of chronic disease prevention and treatment, as well as health management. We are also making every effort to assist China in grass root medical personnel training, in order to fully contribute to the realization of the tiered diagnosis and treatment system,” said Wei Jiang, the Executive Vice President of Commercial Operations, Bayer Pharmaceuticals China & APAC Region and Managing Director of Bayer Pharmaceuticals China.

For the past 10 years, the company has established “Bayer Health Houses” in hundreds of hospitals and community healthcare centers as platforms for healthcare consultation and public healthcare education on diabetes. Meanwhile, through the Go West Project, Bayer has been providing county hospital doctors and executives in China with comprehensive trainings covering diagnosis and treatment techniques, as well as hospital management. From 2007 to October 2016, the Go West Project has reached out to more than 30,000 doctors and hospital executives in 26 provinces with 233 training courses.



*Healthcare experts and Bayer executives staged a panel discussion themed “Enhancing Chronic Disease Management, Shaping a Healthy China”*

At the inauguration ceremony, healthcare experts from home and abroad, and Bayer executives staged a panel discussion themed “Enhancing Chronic Disease Management, Shaping a Healthy China.” To curtail the chronic disease challenges in China, consensus was reached on the necessity to establish a societal management system for chronic diseases centering on integrated management, prioritizing public healthcare education and is underpinned by professional education, which requires collective efforts from all stakeholders including regulators, associations, healthcare professionals, academic institutions, media and enterprises. In the future, Bayer will closely collaborate with partners in China’s healthcare landscape to facilitate more breakthroughs in China’s chronic disease management capabilities.

---

[3] *Blue Paper on Self-Medication in China (2015-2016)*

[4] *WHO, NCD Global Monitoring Framework* → [http://www.who.int/nmh/global\\_monitoring\\_framework/en/](http://www.who.int/nmh/global_monitoring_framework/en/)

### **Bayer: Science For A Better Life**

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to [www.bayer.com](http://www.bayer.com/) → <http://www.bayer.com/>.

## **Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at [www.bayer.com](http://www.bayer.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.